Sonoma Biotherapeutics has raised $265 million in investment funding to support the development and production of novel immune T-cell…
Articles by Steve Bryson, PhD
Clene’s investigational oral therapy CNM-Au8 improved energy metabolism in the brain of adults with relapsing-remitting multiple sclerosis…
High-dose biotin aided walking speed in people with progressive multiple sclerosis after 12 to 15 months as an add-on…
Accessing healthcare providers knowledgeable about multiple sclerosis (MS) and being able to afford additional services to improve overall health…
The low-fat Swank diet and the Wahls elimination diet reduced fatigue and improved quality of life after three months for…
Tysabri (natalizumab) given every six weeks was as safe and effective over nearly 1.5 years of use as its…
Genetic susceptibility to multiple sclerosis (MS) depends on an individual’s particular combination of multiple risk variants, a study reveals.
A component of yeast cell walls — called MGCP — prevented disease in a mouse model of multiple sclerosis…
A potential anti-inflammatory treatment, xB3-IL-1RA was able to reach the central nervous system of a rodent model of multiple…
Nvidia announced the launch of the U.K.’s most powerful supercomputer — called Cambridge-1 — which uses a combination of…
High-potency therapies are more effective at reducing the frequency of symptom relapses in people with secondary progressive multiple sclerosis…
Using high-efficacy therapies as a first treatment for multiple sclerosis (MS) patients significantly increases the likelihood of having no…
The enzyme TET1, which is progressively lost with age, is essential to activate genes needed to repair myelin…
John and Catherine Seibyl, both alumni of Case Western Reserve University (CWRU) in Ohio, have pledged $7.5 million to the…
Gilenya (fingolimod) at its approved 0.5 mg daily dose continues to be the optimal dose for people with relapsing-remitting MS…
Urinary problems, such as an urgency to urinate or a feeling of incomplete urination, are common among people…
Markedly low levels of a simple amino sugar called N-acetylglucosamine (GlcNAc) were found in the bloodstream of people…
Lower antibody levels in the bloodstream and younger age are associated with a greater likelihood of infection in people with…
The digital therapeutics company MedRhythms is launching a clinical trial to evaluate the safety…
LIF, a protein with anti-inflammatory and neuroprotective properties, can be successfully delivered to immune cells in the brain using…
B-cell-depleting therapies given to adults with multiple sclerosis (MS) affect the production of…
The Autoimmune Registry (ARI) has opened a fundraiser, called “Cure the Mother’s Disease,”…
Certain fat molecules produced by gut microbes, which have protective immune-suppressing effects and may protect against multiple…
A short film produced for Hispanic/Latinx people who live with multiple sclerosis (MS)…
Treatment with Zeposia (ozanimod) significantly reduces the risk of relapse, decreases the proportion of patients…
Interim data from a Phase 2 trial of Immunic Therapeutics’ investigational oral therapy IMU-838 (vidofludimus calcium)…
The 2021 John Dystel Prize for multiple sclerosis (MS) research has been awarded…
A 78-year-old man with multiple sclerosis (MS) developed the brain infection progressive multifocal leukoencephalopathy…
A decline in the activity of the GPR17 gene is responsible for age-related brain…
A healthy diet led to better physical and mental quality of life in Dutch adults with…